This technology is a tri-specific antibody targeting multiple epitopes of the human immunodeficiency virus (HIV) for immunotherapy against HIV infection and prevention of viral transmission.
Current methods to treat human immunodeficiency virus (HIV) require daily pills and expensive regimes for the lifetime of the patient. Alternatives in development include antibody therapy applied biannually, including monoclonal and bispecific antibodies which may also decrease the reservoir of infected T cells. However, long term HIV requires at least three different antiretroviral molecules to effectively suppress the virus and there are no HIV antibody therapies on the market.
This technology describes a tri-specific HIV targeted humanized antibody. This therapeutic antibody targets three regions on the HIV viral envelope. Since HIV variants have resistance through viral escape methods, including mutations at the viral surface, multiple viral targets are needed for long-term HIV treatment. This technology targets three distinct regions on the HIV viral envelope with the same antibody formulation.
This technology has been validated in vivo with pharmacokinetic studies in mice.
Patent Issued (US 10,654,943)
IR CU22364
Licensing Contact: Kristin Neuman
